FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19
The FDA has revised the EUA to authorize bamlanivimab and etesevimab monoclonal antibody therapy when administered together for post-exposure prevention in certain individuals who are at high risk for severe infection or death; people should consult with their healthcare provider to find out if this post-exposure therapy is appropriate for them. A monoclonal antibody is …
